SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Metra, M.
Right arrow Articles by Dei Cas, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metra, M.
Right arrow Articles by Dei Cas, L.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Heart Failure
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Current guidelines in the pharmacological management of chronic heart failure

Marco Metra

Cardiologia, Dipartimento di Università di Brescia, Brescia, Italy, metramarco@ libero.it

Savina Nodari

Cardiologia, Dipartimento di Università di Brescia, Brescia, Italy

Livio Dei Cas

Cardiologia, Dipartimento di Università di Brescia, Brescia, Italy

Treatment of heart failure has undergone major changes in the last two decades. European and US guidelines have absorbed these major changes and set the new standards. It is therefore mandatory that treatment of heart failure is based on this knowledge. According to these guidelines, patients with chronic symptomatic heart failure should be treated with a diuretic and sometimes digoxin and vasodilators, to relieve symptoms, in addition to an angiotensin-converting enzyme inhibitor and/or an angiotensin receptor blocker (ARB) and a β-blocker to improve prognosis. An aldosterone antagonist should be added in patients with more advanced heart failure. Prevention of heart failure has also become a major goal.

We summarise here the major issues regarding the pharmacological treatment of chronic heart failure as indicated by the European and US guidelines.

Key Words: heart failure • guidelines • diuretics • β-blockers • angiotensin-converting enzyme inhibitors • cardiac glycosides • angiotensin receptor blockers • aldosterone antagonists

References

  • Murray-Thomas T., Cowie MR Epidemiology and clinical aspects of congestive heart failure. JRAAS 2003;4:131-6.[Medline] [Order article via Infotrieve]
  • Cleland JG, Khand A., Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623-6.[Free Full Text]
  • MacIntyre K., Capewell S., Stewart S. et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126-31.[Abstract/Free Full Text]
  • Roger VL, Weston SA, Redfield MM et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344-50.[Abstract/Free Full Text]
  • Schaufelberger M., Swedberg K., Koster M., Rosen M., Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J 2004;25:300-07.[Abstract/Free Full Text]
  • Hunt SA, Baker DW, Chin MH et al. American College of Cardiology/American Heart Association guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). 2001 American College of Cardiology Web site. Available at: www.acc.org/clinical/guidelines/failure/hf_index.htm
  • Remme WJ, Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.[Free Full Text]
  • Swedberg K. Personal communication.
  • McMurray J., Cohen-Solal A., Dietz R. et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail 2001;3:495-502.[Abstract/Free Full Text]
  • Baker DW Prevention of heart failure. J Card Fail 2002;8:333-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Linseman JV, Bristow MR Drug therapy and heart failure prevention. Circulation 2003; 107:1234-6.[Free Full Text]
  • Dei Cas L., Metra M., Nodaris, Dei Cas A., Gheorghiade M. Prevention and management of chronic heart failure in patients at risk. Am J Cardiol 2003;91:10F-17F.[Web of Science][Medline] [Order article via Infotrieve]
  • Kenchaiah S., Evans JC, Levy D. et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13.[Abstract/Free Full Text]
  • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.to Prevent[Abstract/Free Full Text]
  • Julius S., Kjeldsen SE, Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pahor M., Psaty BM, Alderman MH et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials.Lancet 2000;356:1949-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Neal B., MacMahon S., Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003;362;1527-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Davis BR, Cutler JA, Furberg CD et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart AttackTrial. Ann Intern Med 2002;137(5 Part 1):313-20.[Abstract/Free Full Text]
  • Fox KM EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Arnold JM,Yusuf S.,Young J. et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulatio 2003;107:1284-90.[CrossRef]
  • Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.[Abstract]
  • The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
  • The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-91.[Abstract]
  • Pfeffer MA, Braunwald E., Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.[Abstract]
  • Torp-Pedersen C., Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354:9-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Flather M., Yusuf S., Kober L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients.ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Greenberg BH Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials. J Card Fail 2002;8(6 Suppl):S486-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cleland JG ACE inhibitors for 'diastolic' heart failure? reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure. Eur J Heart Fail 2001;3:637-9.[Free Full Text]
  • Cody RJ, CovitAB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J. Sodium and water balance in chronic congestive heart failure. J Clin Invest 1986;77:1441-52.[Web of Science][Medline] [Order article via Infotrieve]
  • Cody RJ, Franklin KW, Laragh JH Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. Am Heart J 1982;103:480-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Packer M., Lee WH, Medina N., Yushak M., Kessler PD Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987;106:346-54.[Abstract/Free Full Text]
  • Packer M. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure Circulation 1988;77(6 Pt 2):164-73.
  • Packer M., Lee WH, Medina N.,Yushak M., Kessler PD, Gottlieb SS Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. Am J Med 1987;82:1119-26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. introducing diuretics. Br Heart J 1987;57:17-22. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987:5717-22.
  • Kaddoura S., Patel D., Parameshwar J. et al. Objective assessment of the response to treatment of severe heart failure using a 9-minute walk test on a patient-powered treadmill. J Card Fail 1996;2:133-9.[CrossRef][Medline] [Order article via Infotrieve]
  • Braunschweig F., Linde C., Eriksson MJ, Hofman-Bang C., Ryden L. Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. Eur Heart J 2002;23:59-69.[Abstract/Free Full Text]
  • Cooper HA, Dries DL, Davis ECE, Shen YL, Domanski MJ Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100:1311-15.[Abstract/Free Full Text]
  • Neuberg GW, Miller AB, O'Connor CM et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • KiyingiA, Field MJ, Pawsey CC,Yiannikas J., Lawrence JR,Arter WJ Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990;335:29-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bristow MR Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.[Free Full Text]
  • Metra M., Nodari S., D'Aloia A., Bontempi L., Boldi E., Dei Cas L. A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J 2000;139:511-21.[Web of Science][Medline] [Order article via Infotrieve]
  • The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357:1385-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Packer M., Bristow MR, Cohn JN et al.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-55.[Abstract/Free Full Text]
  • Packer M., Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-8.[Abstract/Free Full Text]
  • The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.Lancet 1999;353:9-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 1999;353:2001-07.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Colucci WS, Packer M., Bristow MR et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-06.[Abstract/Free Full Text]
  • Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet 1990;336:1-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Beta-Blocker Evaluation of Survival Trial Investigators.A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.[Abstract/Free Full Text]
  • Poole-Wilson PA, Swedberg K., Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Struthers AD Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.[CrossRef][Medline] [Order article via Infotrieve]
  • Weber KT Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.[Free Full Text]
  • Struthers AD Aldosterone: cardiovascular assault. Am Heart J 2002;144(5 Suppl):S2-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.[Abstract/Free Full Text]
  • Pitt B., Zannad F., Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
  • Ostergren J., McMurray JJ Angiotensin receptor blockers in heart failure. JRAAS 2003;4:171-5.receptor blockers in[Medline] [Order article via Infotrieve]
  • Granger CB, McMurray JJ,Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-75.[Abstract/Free Full Text]
  • McMurray JJ, Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pfeffer MA, Swedberg K., Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan1. Lancet 2002;360:752-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 5, No. 1 suppl, S11-S16 (2004)
DOI: 10.3317/jraas.2004.018
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Metra, M.
Right arrow Articles by Dei Cas, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metra, M.
Right arrow Articles by Dei Cas, L.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Heart Failure
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement